When was Interpace Biosciences founded?

Interpace Biosciences was founded in 1986 and raised its 1st funding round 31 years after it was founded.

Where is Interpace Biosciences located?

Interpace Biosciences is headquartered in Parsippany Troy Hills, United States.

How many employees does Interpace Biosciences have?

As of Jul 31, 2026, the latest employee count at Interpace Biosciences is 117.

Is Interpace Biosciences a funded company?

Interpace Biosciences is a funded company, having raised an undisclosed amount across 4 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Jan 20, 2017.

When was the latest funding round of Interpace Biosciences?

Interpace Biosciences' latest funding was a $***** Post IPO round on Oct 11, 2024, with participation from 0 investor.

What is the annual revenue of Interpace Biosciences?

Annual revenue of Interpace Biosciences is between $10M and $50M as on Dec 31, 2025

Where does Interpace Biosciences rank among its competitors?

Interpace Biosciences ranks 50th amongst 752 active competitors, of which 170 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Guardant Health, which secured $350M in Nov, 2025.

Who are the top competitors of Interpace Biosciences?

Interpace Biosciences' top competitors include Guardant Health, Natera and Myriad Genetics. Among them, Guardant Health secured the most recent funding round in November, 2025.

Interpace Biosciences - 2026 Company Profile, Funding, Competitors & Financials

Interpace Biosciences is a public company based in Parsippany Troy Hills (United States), founded in 1986. It operates as a Provider of molecular diagnostic tests and pathology services for cancer diagnosis. Interpace Biosciences has raised an undisclosed amount in funding. The company has 752 active competitors, including 170 funded and 131 that have exited. Its top competitors include companies like Guardant Health, Natera and Myriad Genetics.

Company Details

Provider of molecular diagnostic tests and pathology services for cancer diagnosis. It offers molecular analysis for early cancer diagnosis and treatment. The company provides clinically beneficial, evidence-based molecular diagnostic tests and pathology services.

Website: www.interpace.com/
Social
Email ID: *****@Interpace.com
Phone Number: +1 **********

Key Metrics

Founded Year

1986

Location

Parsippany Troy Hills, United States

Stage

Public

Latest Funding Round

Post IPO, Oct 11, 2024, $*****

Investors

CYwP Funds & 3 more

Ranked

50^th among 752 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2025

Employee Count

117 as on Jul 31, 2026

Similar Companies

Guardant Health & 573 more

Exit Details

Public

View Interpace Biosciences' full profile

Interpace Biosciences is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
INTERPACE DIAGNOSTICS GROUP, INC. CIN: 1054102 , United States, Active		$10M - $50M (As on Dec 31, 2025)	-	-
Interpace Biosciences, Inc. CIN: 22-2919486 , United States, Active	Dec 31, 1985	-	94 (As on Feb 28, 2023)	-

Interpace Biosciences got listed on May 22, 1998.

Click here to take a look at Interpace Biosciences's IPO in detail

Interpace Biosciences has raised funding over 4 rounds. Its first funding round was on Jan 20, 2017. Interpace Biosciences has 4 institutional investors.

Here is the list of recent funding rounds of Interpace Biosciences:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 11, 2024	5701068	Post IPO	3664290	1770290	7970678	2629215
Jan 27, 2020	7918515	Post IPO	6808091	8792587	3589826	1315 Capital & 1 more
Oct 12, 2017	3095217	Post IPO	5140805	1907511	8492563	5935343

Access funding benchmarks and valuations. Sign up today!

View details of Interpace Biosciences's funding rounds and investors

Interpace Biosciences' employee count trend

Interpace Biosciences has 117 employees as of Jul 26. Here is Interpace Biosciences's employee count trend over the years:

Employee count trend for Interpace Biosciences

Uncover Interpace Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Interpace Biosciences include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of Interpace Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Guardant Health 2012, Redwood City (United States), Public	Developer of digital sequencing technology for cancer detection	$557M	Orbimed, Sequoia Capital & 25 others	79/100
2nd	Natera 2004, Redwood City (United States), Public	Developer of cell-free DNA testing for oncology, women’s health, and organ health	$152M	Harmony Partners, Foresite Capital & 17 others	77/100
3rd	Myriad Genetics 1991, United States, Public	Developer of molecular diagnostics and personalized medicine for cancer	-	Grayhawk Capital, TriplePoint Capital & 6 others	72/100
4th	Foundation Medicine 2010, Cambridge (United States), Acquired	Provider of genomics-based diagnostics test for cancer	$96.5M	Deerfield, Google Ventures & 11 others	71/100
5th	Caris Life Sciences 1996, Irving (United States), Public	Developer of panomic disease profiling technologies for cancer precision medicine	$1.23B	Sixth Street, Braidwell & 19 others	70/100
6th	Roche 1896, Basel (Switzerland), Public	Developer of pharmaceuticals and diagnostics kits	-	Gilde Healthcare, Triodos Investment Management ... & 11 others	70/100
7th	Prenetics 2009, Hong Kong (China), Public	Online platform for genetic and diagnostic health testing that helps identify health risks	$67.6M	Apis Partners, Beyond Ventures & 22 others	69/100
8th	BillionToOne 2015, San Francisco (United States), Public	Provider of cell-free cancer liquid biopsy test	$389M	Hummingbird Ventures, Adams Street Partners ... & 31 others	69/100
9th	Foresight Diagnostics 2020, Aurora (United States), Acquired	Developer of minimally-invasive liquid biopsy test for the detection of cancer	$104M	Foresite Capital, Bluebird Ventures & 6 others	66/100
10th	Saga Diagnostics 2016, Morrisville (United States), Acquired	Provider of tests for detection and analysis of circulating tumor DNA	$17.9M	Hadean Ventures, Segulah Medical Acceleration ... & 11 others	64/100
50th	Interpace Biosciences 1986, Parsippany Troy Hills (United States), Public	Provider of molecular diagnostic tests and pathology services for cancer diagnosis	-	CYwP Funds, 1315 Capital & 2 others	50/100